GlassScriptPhysician profile
Amanda Anderson
NPI 1427673797
$4,171.99
in general payments reported to CMS, 2019-2025
12 companies · $2,918 in 2025
The $2,918 reported for 2025 was more than what 92% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $110 · 2022: $15.29 · 2023: $146 · 2024: $984 · 2025: $2,918.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,938 · Education: $109.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,937.50 |
| Education | $109.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $1,280.47 | 2024-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Alkermes, INC. | $628.70 | 2024-2025 | Aristada, Lybalvi, Aristada Initio |
| Lundbeck LLC | $382.42 | 2024-2025 | Abilify Asimtufii, Rexulti, Abilify Maintena |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $319.00 | 2023-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $286.78 | 2022-2025 | Invega Sustenna, Spravato |
| Vanda Pharmaceuticals INC. | $268.67 | 2024-2025 | Fanapt |
| Otsuka America Pharmaceutical, INC. | $268.45 | 2024-2025 | Abilify Asimtufii, Rexulti, Abilify Maintena |
| Abbvie INC. | $247.27 | 2021-2025 | |
| Neurocrine Biosciences, INC. | $180.67 | 2024-2025 | Ingrezza |
| E.R. Squibb & Sons, L.L.C. | $135.88 | 2024-2025 | Cobenfy |
| Axsome Therapeutics, INC. | $126.24 | 2025 | Auvelity |
| Stryker Corporation | $47.44 | 2024 | Bio4 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Anderson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.